Teladoc Health, Inc. (TDOC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Teladoc Health, Inc. (TDOC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Fiscal Year: January - December
Teladoc Health, Inc. (TDOC), listed on the NYSE, has a market capitalization of $966.91M. As of Mar 19, 2026, the stock is trading at $5.42 per share@else an unavailable price , offering investors a clear view of its current market value. Teladoc Health, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of N/A , investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Teladoc Health, Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Teladoc Health, Inc. (TDOC) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Teladoc Health, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Teladoc Health, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Teladoc Health, Inc. is 3.39, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Teladoc Health, Inc. (TDOC) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Teladoc Health, Inc. (TDOC) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Teladoc Health, Inc. (TDOC) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Teladoc Health, Inc.. To access the full SS Score, consider upgrading your subscription.
Teladoc Health, Inc. is a significant player in the industry sector, with a market capitalization of $966.91M and a competitive P/E ratio of N/A . Investors should compare these metrics with industry peers to gauge whether Teladoc Health, Inc. is outperforming or underperforming within its sector.
Teladoc Health, Inc. (TDOC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Teladoc Health Inc. (NYSE: TDOC) shares are up on Tuesday.
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Chuck Divita, chief executive officer, will participate in the B...
Teladoc Health Inc (NYSE: TDOC) posted upbeat results for the fourth quarter on Wednesday.
Teladoc Health (NYSE: TDOC) shares are up on Thursday following the company's latest earnings report, which highlighted a mix of revenue changes across its segments.
Teladoc Health, Inc. (TDOC) Q4 2025 Earnings Call Transcript
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 (“Fourth...
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release fourth quarter 2025 results on Wednesday, February 25, 2...
Teladoc stock price crashed to a record low as demand for its services waned after the pandemic. It plunged to a low of $5.74, down sharply from the all-time high of $308, with its market capitalizati...
Teladoc Health, Inc. is downgraded to Sell due to persistent revenue declines and deteriorating segment economics. TDOC's Q3 2025 revenue fell 2% year-over-year, with U.S. revenue down 5% and BetterHe...
Teladoc Health, Inc. (TDOC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
New capabilities enable Teladoc Health's care teams to address a broader spectrum of health needs, delivering more value in virtual urgent care visits
Teladoc Health, Inc. (TDOC) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
TytoCare's FDA-cleared home diagnostic technology will be integrated with Teladoc Health's Primary360 and 24/7 Care programs, expanding high-quality remote care capabilities in-home capabilities NE...
Teladoc Health continues to see declining revenues and limited growth catalysts, with Q3 results showing a 2.2% YoY revenue decline. TDOC's recent acquisitions, including UpLift and Catapult Health, h...
Teladoc Health, Inc. ( TDOC) Q3 2025 Earnings Call October 29, 2025 5:00 PM EDT Company Participants Michael Minchak - Vice President of Investor Relations Charles Divita - CEO & Director Mala Murthy...
NEW YORK, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2025 (“T...
Wall Street is bracing for a volatile week as several high-profile companies prepare to release third-quarter earnings, with options markets signaling sharp price swings ahead.
Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms Full-Year 2025 Consolidated Outlook Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms ...
NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release third quarter 2025 results on Wednesday, October 29, 202...
New offering aims to address the growing threat of workplace violence in healthcare settings, building on Teladoc Health's suite of AI-enabled solutions.
MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced it has acquired Telecare, an innovative, Australian tech-enabled...
Teladoc Health remains a deep value play at $7, trading at just 5-6x EBITDA, but lacks a clear growth catalyst. Revenue and user metrics are declining across core segments, with BetterHelp and Chronic...
Teladoc's Q2 2025 earnings reaffirm strong free cash flow guidance, with the potential to reach $220 million in the next twelve months. Despite an attractive 7x next year's free cash flow valuation, r...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 216.87M | -23.34% | Est @-23.3% |
| 2026 | 150.86M | -30.44% | Analyst x5 |
| 2027 | 150.70M | -0.10% | Analyst x4 |
| 2028 | 137.02M | -9.08% | Analyst x2 |
| 2029 | 155.25M | 13.30% | Analyst x2 |
| 2030 | 176.12M | 13.45% | Analyst x2 |
| 2031 | 183.11M | 3.97% | Est @4.0% |
| 2032 | 189.61M | 3.55% | Est @3.5% |
| 2033 | 195.76M | 3.25% | Est @3.2% |
| 2034 | 201.33M | 2.84% | Est @2.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 338.56M | 1.00 | 338.56M |
| 2024A | 282.89M | 1.00 | 282.89M |
| 2025E | 216.87M | 1.09 | 199.02M |
| 2026E | 150.86M | 1.19 | 127.04M |
| 2027E | 150.70M | 1.29 | 116.46M |
| 2028E | 137.02M | 1.41 | 97.17M |
| 2029E | 155.25M | 1.54 | 101.03M |
| 2030E | 176.12M | 1.67 | 105.18M |
| 2031E | 183.11M | 1.82 | 100.35M |
| 2032E | 189.61M | 1.99 | 95.35M |
| 2033E | 195.76M | 2.17 | 90.34M |
| 2034E | 201.33M | 2.36 | 85.26M |
| Terminal | 3.19B | 2.36 | 1.35B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.